Oxford Biomedica and Beam Therapeutics sign CAR-T deal
The Pharma Data
AUGUST 4, 2020
The agreement also puts in place a three year clinical supply agreement for the two companies. Under the terms of the deal, Oxford Biomedica will receive an undisclosed upfront payment, with additional payment related to development and manufacturing of lentiviral vectors for use in clinical trials. .
52 
Let's personalize your content